Don’t Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. These Are the Stocks to Watch.

Don’t Count Out Covid-19 Monoclonal Antibody Treatments, Analyst Says. These Are the Stocks to Watch.
·3 min read

Trial results from Merck’s oral Covid-19 antiviral dented the stocks of other biopharma firms that sell monoclonal antibody treatments for the disease.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting